Kineta Inc., of Seattle, completed enrollment of its phase Ib proof-of-concept trial for psoriasis using its drug candidate, ShK-186, an immune-sparing therapeutic in development for a variety of autoimmune diseases. The study is designed to evaluate the effects of biweekly injections of ShK-186 for four weeks in patients with active plaque psoriasis.